Molecure SA banner

Intrinsic Value

The intrinsic value of Molecure SA (1B1) under the Base Case is 0.64 EUR per share. Compared with the current market price of 1.164 EUR, the stock appears Overvalued by 45% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

1B1 Intrinsic Value
€0.64
Overvaluation 45%
Intrinsic Value
Price €1.164

1B1 is cheaper than usual. Still overvalued, but less so than on 87% of days in the past 5 years.

Alert me when 1B1 is below its intrinsic value
Today €0.512 · 56.0% below the current price
Alternatives to 1B1

Fundamental Analysis

What Molecure Does

Pharmaceuticals Health Care

Molecure SA is a Polish biotechnology company that discovers and develops small-molecule medicines, mainly for diseases with few good treatment options. Its work centers on drug research in areas such as inflammation, fibrosis, and cancer, where it tries to identify new biological targets and turn them into drug candidates that can move into clinical testing.

Headquarters
Poland PL
Employees
106
IPO date
Apr 19, 2018
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue 1B1 Research

Decided on Molecure? Get an email when 1B1 reaches the price you’d buy at. Free with an account.

Other Molecure listings

What is the Intrinsic Value of one 1B1 stock?

The intrinsic value for Molecure SA (1B1) under the Base Case is 0.64 EUR.

Is 1B1 stock undervalued or overvalued?

Compared with the current market price of 1.164 EUR, the stock appears Overvalued by 45% .

How reliable are our estimates? See how past valuations played out
Back to Top